GlassScriptPhysician profile
Peter M Belford
NPI 1205877990
$13,636.19
in general payments reported to CMS, 2019-2025
26 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,724 · 2020: $757 · 2021: $623 · 2022: $1,719 · 2023: $3,309 · 2024: $978 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,079 · Travel and Lodging: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,078.70 |
| Travel and Lodging | $1,734.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,143.28 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal |
| Medtronic Vascular, INC. | $2,551.62 | 2019-2020 | |
| Medtronic, INC. | $2,220.79 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Ffrangio |
| Abiomed | $1,554.74 | 2019-2025 | Impella |
| Boston Scientific Corporation | $1,495.35 | 2019-2025 | General - Stents, General - Vascular Intervention, Avvigo Guidance System |
| Angiodynamics, INC. | $435.53 | 2020-2024 | Angiovac |
| Abbott Laboratories | $324.06 | 2019-2025 | Dragonfly Opstar, Diamondback Coronary, Optis |
| Siemens Medical Solutions USA, INC. | $284.18 | 2019-2022 | |
| Inari Medical, INC. | $263.29 | 2020-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Recor Medical INC | $250.89 | 2025 | Paradise Ultrasound Renal Denervation System |
| Corindus INC. | $228.66 | 2019 | |
| Shockwave Medical, INC | $217.09 | 2022-2025 | |
| Amgen INC. | $179.28 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $173.00 | 2019-2022 | |
| Teleflex LLC | $93.12 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.60 | 2021-2022 | |
| Philips North America LLC | $33.02 | 2025 | Coronary Other |
| Novartis Pharmaceuticals Corporation | $30.64 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.69 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.15 | 2021-2022 | |
| Pfizer INC. | $16.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.30 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.89 | 2024 | Lifevest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Belford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.